NCT02766686Completed
Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons
Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons in Standard Fractionation and Standard Dosage
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
ProtoChoice-P is a prospective multicenter trial to evaluate proton therapy in patients suffering from prostate cancer. Primary aim of the study is a decrease of moderate or severe genito-urinary or intestinal side effects (Common Terminology Criteria for Adverse Events (CTCAE) 4.0 grade 2 or higher) by the use of proton therapy. Secondary endpoints contain assessment of quality of life, biochemical recurrence and recurrence free survival as well as overall survival and economic comparison between photon and proton therapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 180 (actual)
- First submitted
- 9 May 2016
- Start date
- 1 Sept 2016
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Technische Universität Dresden
- Diseases
- Prostate cancer
- NCT number
- NCT02766686
What you commit to
- Study type: Interventional
- Participants enrolled: 180
- From 1 Sept 2016 to the primary completion date, 28 Feb 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous radiotherapy of the lesser pelvis
- previous or concomitant other malignant disease except when there is no impact on treatment or follow-up of the prostate cancer
Other
- distant metastases
- participation in another clinical study, if it's excluded by the study protocols
Who the study is looking for
- life expectancy ≥ 10 years
- adenocarcinoma of the prostate confirmed by punch biopsy
- locally limited to locally advanced adenocarcinomas without evidence of distant metastases i.e. T1-3b N0-1 M0
- stage-related indicated neoadjuvant / adjuvant androgen deprivation possible (neoadjuvant ≤ 6 months)
- good general condition (ECOG performance status 0 - 1)
- marker seed implantation before irradiation (optional) or possibility of Image-guided Radiation Therapy (IGRT) by CT
- adequate compliance for follow-up
- written informed consent
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology Coordinator of this site? Confirm its status | Dresden | Germany | Unknown status |
| Klinikum rechts der Isar Technische Universität München Coordinator of this site? Confirm its status | Munich | Germany | Unknown status |
| Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen Coordinator of this site? Confirm its status | Tübingen | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.